THERAPEUTICSMD INC. overview

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, announced today that the Company submitted a supplemental New Drug Application (“sNDA”) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the U.S. Food and Drug Administration (“FDA”). The Company expects to learn of the acceptance of the sNDA upon receipt of the Filing Review Notification from the FDA, approximately 74 days after submission. If accepted, the Company expects that...

TherapeuticsMD, Inc. (NASDAQ: TXMD), has been awarded a Top Workplaces 2021 honor by The Sun Sentinel. The list is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage , LLC. The anonymous survey uniquely measures 15 culture drivers that are critical to the success of any organization including alignment, execution, and connection. “During this very challenging time, Top Workplaces has proven to be a beacon of...

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare Company, today reported financial results for the first quarter ended March 31, 2021. “I am pleased with our ongoing execution across the organization, which is in-line with our 2021 operating plan led by ANNOVERA, which performed well in a challenging environment. Our financial performance continues to improve year-over-year. Both menopausal products, IMVEXXY and BIJUVA, had record net revenue per unit. We are...

NEW YORK, NY / ACCESSWIRE / August 3, 2017 / TherapeuticsMD, Inc. (NYSE American: TXMD ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 3, 2017 at 4:30 PM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/3688 . Replay Information The replay will be available online at https://www.investornetwork.com/company/3688 . About Investor Network Investor Network (IN) is a new financial content community,...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TherapeuticsMD, Inc. of Class Action Lawsuit and Upcoming Deadline - TXMD PR Newswire NEW YORK, June 16, 2017 NEW YORK , June 16, 2017 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE: TXMD) and certain of its officers. The class action, filed in United States District Court, Southern District of...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TherapeuticsMD, Inc. - TXMD PR Newswire NEW YORK, May 10, 2017 NEW YORK , May 10, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE: TXMD). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The investigation concerns whether TherapeuticsMD and certain of...

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In TherapeuticsMD, Inc. To Contact The Firm PR Newswire NEW YORK, May 9, 2017 NEW YORK , May 9, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE-MKT: TXMD) of the June 19, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company...

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm PR Newswire IRVINE, Calif., May 3, 2017 IRVINE, Calif. , May 3, 2017 /PRNewswire/ -- Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE: TXMD). Investors who purchased or otherwise acquired shares between July 7, 2016 and April...